Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: A retrospective multicenter study

Retina

Volumn 34, Issue 1, 2014, Pages 12-17

  Casparis, Heather ^a   Wolfensberger, Thomas J ^a   Becker, Matthias ^b   Eich, Gerhard ^b   Graf, Nicole ^c   Ambresin, Aude ^a   Mantel, Irmela ^a   Michels, Stephan ^b  

^a JULES GONIN EYE HOSPITAL   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c Department of Graf Biostatistics ^*  (Switzerland)

Author keywords

Aflibercept; Bevacizumab; Endophthalmitis; Intravitreal injection; Operating room; Pegaptanib; Ranibizumab; Safety

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

AGED; ANTERIOR EYE CHAMBER; ARTICLE; ENDOPHTHALMITIS; FEMALE; HUMAN; INCIDENCE; OPERATING ROOM; VERY ELDERLY; VITREOUS BIOPSY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; ENDOPHTHALMITIS; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; OPERATING ROOMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SWITZERLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891888689     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31829f74b0     Document Type: Article

References (34)

1. Martin DF, Maguire MG, Fine SL, et al; Comparison of Agerelated Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
2. Elman MJ, Qin H, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119: 2312-2318.
3. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-2049.
4. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-895.
5. ONE Network: American Academy of Ophthalmology. Available at: http://one.aao.org/CE/PracticeGuidelines/ClinicalStatements- Content.aspx?cid=404813e9-b3dc-4d6d-a2c5-d1f1e78a926b. Accessed December 12, 2012.
6. Michels S, Becker M, Wachtlin J, Binder S. The intravitreal injection: variations in regulations, cost and reimbursement in Europe. Spektrum der Augenheilkunde 2012;26:2-6.
7. Meyer CH, Michels S, Rodrigues EB, et al. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011;89:70-75.
8. Meyer CH, Rodrigues EB, Michels S, et al. Incidence of damage to the crystalline lens during intravitreal injections. J Ocul Pharmacol Ther 2010;26:491-495.
9. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995; 113:1479-1496.
10. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Retina 2011;31:654-661.
11. Goldberg RA, Flynn HW Jr, Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153:204-208.
12. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
13. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355: 1432-1444.
14. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119: 2537-2548.
15. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011;31:662-668.
16. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151:329-332.
17. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 2012;96: 1474-1478.
18. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol 2007;27:307-312.
19. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116: 1498-1501.
20. Ikuno Y, Sawa M, Tsujikawa M, et al. Effectiveness of 1.25% povidone-iodine combined with topical levofloxacin against conjunctival flora in intravitreal injection. Jpn J Ophthalmol 2012;56:497-501.
21. Moss JM, Sanislo SR, Ta CN. Antibiotic 200 susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology 2012;117:2141-2145.
22. Alabiad CR, Miller D, Schiffman JC, Davis JL. Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol 2011; 152:999-1004.
23. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol 2011;129:1180-1188.
24. Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012;119:1420-1424.
25. Cheung CSY, Wong AWT, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609-1614.
26. Bhavsar AR, Stockdale CR, Ferris FL, et al; Diabetic Retinopathy Clinical Research Network. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130: 809-810.
27. Rogers DL, Chheda L, Ford C, et al. The effect of surgical preparation technique on the bacterial load of surgical needles and suture material used during strabismus surgery. J AAPOS 2011;15:230-233.
28. de Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008;28:877-883.
29. Nentwich M, Yactayo-Miranda Y, Weimann S, et al. Bacterial contamination of needle points after intravitreal injection. Eur J Ophthalmol 2009;19:268-271.
30. Stewart JM, Srivastava SK, Fung AE, et al. Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. Ocul Immunol Inflamm 2011;19:32-38.
31. Gines JC, Nentwich MM, Peggy Bedoya AH, et al. Bacterial contamination of needles after intravitreal injection in Paraguay [in German]. Ophthalmologe 2012;109:782-787.
32. Melhado MA, Hensen JLM, Loomans M, Forejt L. Review of operating room ventilation standards. Proceedings of the 17th International Air-conditioning and Ventilation Conference 2006. Prague, Czech Republic: STP-Society of Environmental Engineering, 2006. Available at: http://www.bwk.tue.nl/bps/hensen/ publications/06-iprc-melhado.pdf. Accessed August 8, 2013.
33. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol 2011;129:1551-1554.
34. Doshi RR, Leng T, Fung AE. Reducing oral contamination of intravitreal injections with face mask or silence. Retina 2012; 32:473-476.